Arcadia Biosciences, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Arcadia Biosciences adopted the 2026 Omnibus Equity Incentive Plan, authorizing 400,000 shares for grant as stock options, restricted stock, RSUs, SARs, and performance awards to employees, directors, and contractors. The plan auto-increases by 4% annually (or board-determined amount, whichever is less) starting January 1, 2027. No specific awards were granted in this filing—only the plan and form templates were disclosed. All awards require stockholder approval within 12 months.
Why this rating
Plan adoption is routine administrative governance. 400k share reserve on ~$5.7M market cap (~7% fully diluted if fully used) is standard for micro-cap; no awards granted yet. No immediate capital dilution or business change.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.